AlphaCore Aiming High with Recombinant LCAT
AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, befitting a biotech working in the rare orphan indication of familial LCAT deficiency. The inherited condition causes corneal opacities, anemia and renal disease due to the accumulation of LCAT substrates (unesterified cholesterol and phospholipid).
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST